A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions

Adebrelimab (SHR-1316)XELOXGC/GEJC

Interventions

DRUG

Adebrelimab

Adebrelimab:1200 mg, iv, d1

DRUG

XELOX

oxaliplatin: 130 mg/m2,iv,d1; capecitabine: 1000 mg/m2,po,pid,d1-d14

Trial Locations (1)

RECRUITING

Tianjin Cancer Institute and Hospital, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER